nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ORM1—Vandetanib—thyroid cancer	0.222	0.297	CbGbCtD
Canagliflozin—UGT1A9—Sorafenib—thyroid cancer	0.182	0.243	CbGbCtD
Canagliflozin—ALB—Vandetanib—thyroid cancer	0.0934	0.125	CbGbCtD
Canagliflozin—ABCC2—Sorafenib—thyroid cancer	0.0903	0.121	CbGbCtD
Canagliflozin—ABCC2—Doxorubicin—thyroid cancer	0.0548	0.0734	CbGbCtD
Canagliflozin—Glucose low—Vandetanib—thyroid cancer	0.0387	0.214	CcSEcCtD
Canagliflozin—ABCB1—Sorafenib—thyroid cancer	0.0294	0.0394	CbGbCtD
Canagliflozin—CYP3A4—Vandetanib—thyroid cancer	0.0293	0.0392	CbGbCtD
Canagliflozin—ABCB1—Doxorubicin—thyroid cancer	0.0179	0.0239	CbGbCtD
Canagliflozin—CYP3A4—Sorafenib—thyroid cancer	0.0176	0.0236	CbGbCtD
Canagliflozin—Blood glucose decreased—Vandetanib—thyroid cancer	0.0123	0.068	CcSEcCtD
Canagliflozin—CYP3A4—Doxorubicin—thyroid cancer	0.0107	0.0143	CbGbCtD
Canagliflozin—Blood potassium increased—Vandetanib—thyroid cancer	0.00922	0.0511	CcSEcCtD
Canagliflozin—Micturition urgency—Vandetanib—thyroid cancer	0.00491	0.0272	CcSEcCtD
Canagliflozin—Serum creatinine increased—Vandetanib—thyroid cancer	0.00453	0.0251	CcSEcCtD
Canagliflozin—SLC5A1—Hexose uptake—TPR—thyroid cancer	0.00347	0.0478	CbGpPWpGaD
Canagliflozin—SLC5A2—Hexose uptake—TPR—thyroid cancer	0.00347	0.0478	CbGpPWpGaD
Canagliflozin—UGT2B4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.00342	0.0471	CbGpPWpGaD
Canagliflozin—Cystitis noninfective—Vandetanib—thyroid cancer	0.00272	0.0151	CcSEcCtD
Canagliflozin—Cystitis—Vandetanib—thyroid cancer	0.00269	0.0149	CcSEcCtD
Canagliflozin—Bladder pain—Vandetanib—thyroid cancer	0.00252	0.014	CcSEcCtD
Canagliflozin—Hypoglycaemia—Vandetanib—thyroid cancer	0.00207	0.0115	CcSEcCtD
Canagliflozin—UGT2B4—Metapathway biotransformation—CHST14—thyroid cancer	0.00199	0.0274	CbGpPWpGaD
Canagliflozin—SLC5A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.00191	0.0263	CbGpPWpGaD
Canagliflozin—SLC5A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.00191	0.0263	CbGpPWpGaD
Canagliflozin—Blood creatinine increased—Vandetanib—thyroid cancer	0.00189	0.0105	CcSEcCtD
Canagliflozin—SLC5A1—Carbohydrate metabolism—CHST14—thyroid cancer	0.00188	0.0259	CbGpPWpGaD
Canagliflozin—SLC5A2—Carbohydrate metabolism—CHST14—thyroid cancer	0.00188	0.0259	CbGpPWpGaD
Canagliflozin—Dehydration—Vandetanib—thyroid cancer	0.00188	0.0104	CcSEcCtD
Canagliflozin—Rash papular—Epirubicin—thyroid cancer	0.00186	0.0103	CcSEcCtD
Canagliflozin—Rash papular—Doxorubicin—thyroid cancer	0.00172	0.00956	CcSEcCtD
Canagliflozin—Pancreatitis—Vandetanib—thyroid cancer	0.00171	0.0095	CcSEcCtD
Canagliflozin—Pollakiuria—Vandetanib—thyroid cancer	0.00161	0.00895	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Vandetanib—thyroid cancer	0.0016	0.00885	CcSEcCtD
Canagliflozin—Urinary tract infection—Vandetanib—thyroid cancer	0.00151	0.0084	CcSEcCtD
Canagliflozin—Renal failure acute—Sorafenib—thyroid cancer	0.00148	0.00819	CcSEcCtD
Canagliflozin—Urinary tract disorder—Vandetanib—thyroid cancer	0.00138	0.00766	CcSEcCtD
Canagliflozin—Urethral disorder—Vandetanib—thyroid cancer	0.00137	0.0076	CcSEcCtD
Canagliflozin—Vulvovaginal candidiasis—Epirubicin—thyroid cancer	0.00132	0.00732	CcSEcCtD
Canagliflozin—Vulvovaginal mycotic infection—Epirubicin—thyroid cancer	0.00127	0.00704	CcSEcCtD
Canagliflozin—Angiopathy—Vandetanib—thyroid cancer	0.00127	0.00704	CcSEcCtD
Canagliflozin—Dehydration—Sorafenib—thyroid cancer	0.00127	0.00703	CcSEcCtD
Canagliflozin—Breast disorder—Sorafenib—thyroid cancer	0.00123	0.00684	CcSEcCtD
Canagliflozin—Vulvovaginal candidiasis—Doxorubicin—thyroid cancer	0.00122	0.00678	CcSEcCtD
Canagliflozin—Malnutrition—Vandetanib—thyroid cancer	0.00122	0.00675	CcSEcCtD
Canagliflozin—Vulvovaginal mycotic infection—Doxorubicin—thyroid cancer	0.00118	0.00652	CcSEcCtD
Canagliflozin—Pancreatitis—Sorafenib—thyroid cancer	0.00116	0.00641	CcSEcCtD
Canagliflozin—SLC5A2—Orphan transporters—RXRA—thyroid cancer	0.00114	0.0156	CbGpPWpGaD
Canagliflozin—SLC5A1—Orphan transporters—RXRA—thyroid cancer	0.00114	0.0156	CbGpPWpGaD
Canagliflozin—Serum creatinine increased—Epirubicin—thyroid cancer	0.00113	0.00626	CcSEcCtD
Canagliflozin—Loss of consciousness—Vandetanib—thyroid cancer	0.00107	0.00593	CcSEcCtD
Canagliflozin—UGT1A9—PPAR Alpha Pathway—CDK1—thyroid cancer	0.00106	0.0146	CbGpPWpGaD
Canagliflozin—Convulsion—Vandetanib—thyroid cancer	0.00106	0.00585	CcSEcCtD
Canagliflozin—Serum creatinine increased—Doxorubicin—thyroid cancer	0.00104	0.00579	CcSEcCtD
Canagliflozin—SLC5A2—NRF2 pathway—SLC5A5—thyroid cancer	0.00103	0.0142	CbGpPWpGaD
Canagliflozin—SLC5A1—NRF2 pathway—SLC5A5—thyroid cancer	0.00103	0.0142	CbGpPWpGaD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00103	0.00571	CcSEcCtD
Canagliflozin—Dry mouth—Vandetanib—thyroid cancer	0.00101	0.00562	CcSEcCtD
Canagliflozin—Infection—Vandetanib—thyroid cancer	0.000987	0.00547	CcSEcCtD
Canagliflozin—UGT1A9—PPAR Alpha Pathway—RXRA—thyroid cancer	0.000985	0.0136	CbGpPWpGaD
Canagliflozin—Nervous system disorder—Vandetanib—thyroid cancer	0.000975	0.0054	CcSEcCtD
Canagliflozin—Skin disorder—Vandetanib—thyroid cancer	0.000965	0.00535	CcSEcCtD
Canagliflozin—Urinary tract disorder—Sorafenib—thyroid cancer	0.000932	0.00517	CcSEcCtD
Canagliflozin—Urethral disorder—Sorafenib—thyroid cancer	0.000925	0.00513	CcSEcCtD
Canagliflozin—Rash erythematous—Epirubicin—thyroid cancer	0.000907	0.00503	CcSEcCtD
Canagliflozin—SLC5A2—Carbohydrate metabolism—TPR—thyroid cancer	0.000871	0.012	CbGpPWpGaD
Canagliflozin—SLC5A1—Carbohydrate metabolism—TPR—thyroid cancer	0.000871	0.012	CbGpPWpGaD
Canagliflozin—Rash pustular—Epirubicin—thyroid cancer	0.000871	0.00483	CcSEcCtD
Canagliflozin—SLC5A2—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000869	0.012	CbGpPWpGaD
Canagliflozin—SLC5A2—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000869	0.012	CbGpPWpGaD
Canagliflozin—SLC5A1—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000869	0.012	CbGpPWpGaD
Canagliflozin—SLC5A1—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000869	0.012	CbGpPWpGaD
Canagliflozin—SLC5A1—NRF2 pathway—RXRA—thyroid cancer	0.000867	0.0119	CbGpPWpGaD
Canagliflozin—SLC5A2—NRF2 pathway—RXRA—thyroid cancer	0.000867	0.0119	CbGpPWpGaD
Canagliflozin—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000858	0.00476	CcSEcCtD
Canagliflozin—Fatigue—Vandetanib—thyroid cancer	0.000857	0.00475	CcSEcCtD
Canagliflozin—Angiopathy—Sorafenib—thyroid cancer	0.000856	0.00475	CcSEcCtD
Canagliflozin—Constipation—Vandetanib—thyroid cancer	0.00085	0.00471	CcSEcCtD
Canagliflozin—Rash erythematous—Doxorubicin—thyroid cancer	0.000839	0.00465	CcSEcCtD
Canagliflozin—ALB—FOXA2 and FOXA3 transcription factor networks—NKX2-1—thyroid cancer	0.000835	0.0115	CbGpPWpGaD
Canagliflozin—UGT1A9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000834	0.0115	CbGpPWpGaD
Canagliflozin—Malnutrition—Sorafenib—thyroid cancer	0.000821	0.00456	CcSEcCtD
Canagliflozin—Erythema—Sorafenib—thyroid cancer	0.000821	0.00456	CcSEcCtD
Canagliflozin—ABCC2—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000814	0.0112	CbGpPWpGaD
Canagliflozin—Gastrointestinal pain—Vandetanib—thyroid cancer	0.000813	0.00451	CcSEcCtD
Canagliflozin—Rash pustular—Doxorubicin—thyroid cancer	0.000806	0.00447	CcSEcCtD
Canagliflozin—Abdominal pain—Vandetanib—thyroid cancer	0.000786	0.00436	CcSEcCtD
Canagliflozin—ALB—Recycling of bile acids and salts—RXRA—thyroid cancer	0.000761	0.0105	CbGpPWpGaD
Canagliflozin—Angioedema—Sorafenib—thyroid cancer	0.000751	0.00416	CcSEcCtD
Canagliflozin—SLC5A1—NRF2 pathway—NRG1—thyroid cancer	0.00075	0.0103	CbGpPWpGaD
Canagliflozin—SLC5A2—NRF2 pathway—NRG1—thyroid cancer	0.00075	0.0103	CbGpPWpGaD
Canagliflozin—Nocturia—Epirubicin—thyroid cancer	0.000749	0.00415	CcSEcCtD
Canagliflozin—Syncope—Sorafenib—thyroid cancer	0.000737	0.00408	CcSEcCtD
Canagliflozin—UGT1A9—Metapathway biotransformation—CHST14—thyroid cancer	0.000736	0.0101	CbGpPWpGaD
Canagliflozin—Loss of consciousness—Sorafenib—thyroid cancer	0.000722	0.004	CcSEcCtD
Canagliflozin—Asthenia—Vandetanib—thyroid cancer	0.000713	0.00395	CcSEcCtD
Canagliflozin—Pruritus—Vandetanib—thyroid cancer	0.000703	0.0039	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000695	0.00385	CcSEcCtD
Canagliflozin—Nocturia—Doxorubicin—thyroid cancer	0.000693	0.00384	CcSEcCtD
Canagliflozin—Dry mouth—Sorafenib—thyroid cancer	0.000684	0.00379	CcSEcCtD
Canagliflozin—Hyperkalaemia—Epirubicin—thyroid cancer	0.000682	0.00378	CcSEcCtD
Canagliflozin—Cystitis noninfective—Epirubicin—thyroid cancer	0.000678	0.00376	CcSEcCtD
Canagliflozin—Cystitis—Epirubicin—thyroid cancer	0.000671	0.00372	CcSEcCtD
Canagliflozin—Infection—Sorafenib—thyroid cancer	0.000666	0.00369	CcSEcCtD
Canagliflozin—Shock—Sorafenib—thyroid cancer	0.00066	0.00366	CcSEcCtD
Canagliflozin—Nervous system disorder—Sorafenib—thyroid cancer	0.000657	0.00365	CcSEcCtD
Canagliflozin—Dizziness—Vandetanib—thyroid cancer	0.000657	0.00364	CcSEcCtD
Canagliflozin—Blood urea increased—Epirubicin—thyroid cancer	0.000656	0.00364	CcSEcCtD
Canagliflozin—Vaginal infection—Epirubicin—thyroid cancer	0.000656	0.00364	CcSEcCtD
Canagliflozin—Skin disorder—Sorafenib—thyroid cancer	0.000651	0.00361	CcSEcCtD
Canagliflozin—SLC5A1—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.00065	0.00895	CbGpPWpGaD
Canagliflozin—SLC5A2—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.00065	0.00895	CbGpPWpGaD
Canagliflozin—Hyperkalaemia—Doxorubicin—thyroid cancer	0.000631	0.0035	CcSEcCtD
Canagliflozin—Rash maculo-papular—Epirubicin—thyroid cancer	0.000631	0.0035	CcSEcCtD
Canagliflozin—Bladder pain—Epirubicin—thyroid cancer	0.000628	0.00348	CcSEcCtD
Canagliflozin—Cystitis noninfective—Doxorubicin—thyroid cancer	0.000628	0.00348	CcSEcCtD
Canagliflozin—Rash—Vandetanib—thyroid cancer	0.000627	0.00347	CcSEcCtD
Canagliflozin—Dermatitis—Vandetanib—thyroid cancer	0.000626	0.00347	CcSEcCtD
Canagliflozin—Cystitis—Doxorubicin—thyroid cancer	0.00062	0.00344	CcSEcCtD
Canagliflozin—Blood urea increased—Doxorubicin—thyroid cancer	0.000607	0.00336	CcSEcCtD
Canagliflozin—Vaginal infection—Doxorubicin—thyroid cancer	0.000607	0.00336	CcSEcCtD
Canagliflozin—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.000598	0.00823	CbGpPWpGaD
Canagliflozin—Nausea—Vandetanib—thyroid cancer	0.00059	0.00327	CcSEcCtD
Canagliflozin—UGT2B4—Biological oxidations—RXRA—thyroid cancer	0.000587	0.00808	CbGpPWpGaD
Canagliflozin—Rash maculo-papular—Doxorubicin—thyroid cancer	0.000584	0.00324	CcSEcCtD
Canagliflozin—Bladder pain—Doxorubicin—thyroid cancer	0.000581	0.00322	CcSEcCtD
Canagliflozin—Diabetes mellitus—Epirubicin—thyroid cancer	0.00058	0.00321	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000579	0.00321	CcSEcCtD
Canagliflozin—Fatigue—Sorafenib—thyroid cancer	0.000578	0.00321	CcSEcCtD
Canagliflozin—Photosensitivity—Epirubicin—thyroid cancer	0.000574	0.00318	CcSEcCtD
Canagliflozin—Constipation—Sorafenib—thyroid cancer	0.000573	0.00318	CcSEcCtD
Canagliflozin—SLC5A2—Disease—TRIM24—thyroid cancer	0.000567	0.0078	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—TRIM24—thyroid cancer	0.000567	0.0078	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—MINPP1—thyroid cancer	0.000559	0.00769	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—MINPP1—thyroid cancer	0.000559	0.00769	CbGpPWpGaD
Canagliflozin—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000548	0.00304	CcSEcCtD
Canagliflozin—Renal failure acute—Epirubicin—thyroid cancer	0.000546	0.00303	CcSEcCtD
Canagliflozin—Diabetes mellitus—Doxorubicin—thyroid cancer	0.000536	0.00297	CcSEcCtD
Canagliflozin—SLC5A1—Disease—CHST14—thyroid cancer	0.000533	0.00734	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CHST14—thyroid cancer	0.000533	0.00734	CbGpPWpGaD
Canagliflozin—Urticaria—Sorafenib—thyroid cancer	0.000533	0.00295	CcSEcCtD
Canagliflozin—Photosensitivity—Doxorubicin—thyroid cancer	0.000531	0.00295	CcSEcCtD
Canagliflozin—Abdominal pain—Sorafenib—thyroid cancer	0.00053	0.00294	CcSEcCtD
Canagliflozin—Hypoglycaemia—Epirubicin—thyroid cancer	0.000517	0.00286	CcSEcCtD
Canagliflozin—SLC5A1—Disease—TRIM33—thyroid cancer	0.000505	0.00695	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—TRIM33—thyroid cancer	0.000505	0.00695	CbGpPWpGaD
Canagliflozin—Renal failure acute—Doxorubicin—thyroid cancer	0.000505	0.0028	CcSEcCtD
Canagliflozin—Hypersensitivity—Sorafenib—thyroid cancer	0.000494	0.00274	CcSEcCtD
Canagliflozin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.00049	0.00674	CbGpPWpGaD
Canagliflozin—Asthenia—Sorafenib—thyroid cancer	0.000481	0.00267	CcSEcCtD
Canagliflozin—Hypoglycaemia—Doxorubicin—thyroid cancer	0.000478	0.00265	CcSEcCtD
Canagliflozin—SLC5A2—Metabolism—NDUFA13—thyroid cancer	0.000475	0.00653	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—NDUFA13—thyroid cancer	0.000475	0.00653	CbGpPWpGaD
Canagliflozin—Pruritus—Sorafenib—thyroid cancer	0.000474	0.00263	CcSEcCtD
Canagliflozin—Blood creatinine increased—Epirubicin—thyroid cancer	0.000472	0.00262	CcSEcCtD
Canagliflozin—Dehydration—Epirubicin—thyroid cancer	0.000469	0.0026	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00046	0.00255	CcSEcCtD
Canagliflozin—Breast disorder—Epirubicin—thyroid cancer	0.000456	0.00253	CcSEcCtD
Canagliflozin—SLC5A1—Metabolism—CHST14—thyroid cancer	0.000447	0.00614	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—CHST14—thyroid cancer	0.000447	0.00614	CbGpPWpGaD
Canagliflozin—Dizziness—Sorafenib—thyroid cancer	0.000443	0.00246	CcSEcCtD
Canagliflozin—UGT1A9—PPAR Alpha Pathway—CCND1—thyroid cancer	0.000442	0.00608	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—CP—thyroid cancer	0.000441	0.00607	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000441	0.00607	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000441	0.00607	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—CP—thyroid cancer	0.000441	0.00607	CbGpPWpGaD
Canagliflozin—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000437	0.00242	CcSEcCtD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000434	0.00597	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000434	0.00597	CbGpPWpGaD
Canagliflozin—Dehydration—Doxorubicin—thyroid cancer	0.000434	0.00241	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—MINPP1—thyroid cancer	0.000431	0.00593	CbGpPWpGaD
Canagliflozin—Pancreatitis—Epirubicin—thyroid cancer	0.000427	0.00237	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000426	0.00236	CcSEcCtD
Canagliflozin—Rash—Sorafenib—thyroid cancer	0.000423	0.00234	CcSEcCtD
Canagliflozin—Dermatitis—Sorafenib—thyroid cancer	0.000422	0.00234	CcSEcCtD
Canagliflozin—Breast disorder—Doxorubicin—thyroid cancer	0.000422	0.00234	CcSEcCtD
Canagliflozin—Pollakiuria—Epirubicin—thyroid cancer	0.000403	0.00223	CcSEcCtD
Canagliflozin—Nausea—Sorafenib—thyroid cancer	0.000398	0.00221	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000398	0.00221	CcSEcCtD
Canagliflozin—ALB—Bile acid and bile salt metabolism—RXRA—thyroid cancer	0.000398	0.00547	CbGpPWpGaD
Canagliflozin—Pancreatitis—Doxorubicin—thyroid cancer	0.000395	0.00219	CcSEcCtD
Canagliflozin—ABCB1—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000383	0.00527	CbGpPWpGaD
Canagliflozin—Urinary tract infection—Epirubicin—thyroid cancer	0.000378	0.00209	CcSEcCtD
Canagliflozin—Pollakiuria—Doxorubicin—thyroid cancer	0.000372	0.00207	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000368	0.00204	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—NDUFA13—thyroid cancer	0.000367	0.00505	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—HPGD—thyroid cancer	0.00036	0.00495	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—HPGD—thyroid cancer	0.00036	0.00495	CbGpPWpGaD
Canagliflozin—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.000358	0.00492	CbGpPWpGaD
Canagliflozin—Urinary tract infection—Doxorubicin—thyroid cancer	0.000349	0.00194	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—CHST14—thyroid cancer	0.000345	0.00474	CbGpPWpGaD
Canagliflozin—Urinary tract disorder—Epirubicin—thyroid cancer	0.000344	0.00191	CcSEcCtD
Canagliflozin—Urethral disorder—Epirubicin—thyroid cancer	0.000342	0.0019	CcSEcCtD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.000341	0.00469	CbGpPWpGaD
Canagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—EPO—thyroid cancer	0.00034	0.00467	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—TCF7L1—thyroid cancer	0.000337	0.00464	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—TCF7L1—thyroid cancer	0.000337	0.00464	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.00033	0.00455	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.00033	0.00455	CbGpPWpGaD
Canagliflozin—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000319	0.00177	CcSEcCtD
Canagliflozin—Angiopathy—Epirubicin—thyroid cancer	0.000316	0.00175	CcSEcCtD
Canagliflozin—Urethral disorder—Doxorubicin—thyroid cancer	0.000316	0.00175	CcSEcCtD
Canagliflozin—UGT1A9—PPARA activates gene expression—RXRA—thyroid cancer	0.000311	0.00427	CbGpPWpGaD
Canagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—thyroid cancer	0.000304	0.00418	CbGpPWpGaD
Canagliflozin—Erythema—Epirubicin—thyroid cancer	0.000304	0.00168	CcSEcCtD
Canagliflozin—Malnutrition—Epirubicin—thyroid cancer	0.000304	0.00168	CcSEcCtD
Canagliflozin—UGT1A9—NRF2 pathway—SLC5A5—thyroid cancer	0.000295	0.00406	CbGpPWpGaD
Canagliflozin—Angiopathy—Doxorubicin—thyroid cancer	0.000293	0.00162	CcSEcCtD
Canagliflozin—ABCC2—NRF2 pathway—SLC5A5—thyroid cancer	0.000288	0.00396	CbGpPWpGaD
Canagliflozin—Malnutrition—Doxorubicin—thyroid cancer	0.000281	0.00156	CcSEcCtD
Canagliflozin—Erythema—Doxorubicin—thyroid cancer	0.000281	0.00156	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—HPGD—thyroid cancer	0.000278	0.00382	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000278	0.00382	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000278	0.00382	CbGpPWpGaD
Canagliflozin—Syncope—Epirubicin—thyroid cancer	0.000272	0.00151	CcSEcCtD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.000268	0.00368	CbGpPWpGaD
Canagliflozin—Loss of consciousness—Epirubicin—thyroid cancer	0.000267	0.00148	CcSEcCtD
Canagliflozin—Convulsion—Epirubicin—thyroid cancer	0.000263	0.00146	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000257	0.00142	CcSEcCtD
Canagliflozin—Dry mouth—Epirubicin—thyroid cancer	0.000253	0.0014	CcSEcCtD
Canagliflozin—Syncope—Doxorubicin—thyroid cancer	0.000252	0.0014	CcSEcCtD
Canagliflozin—UGT1A9—NRF2 pathway—RXRA—thyroid cancer	0.000248	0.00341	CbGpPWpGaD
Canagliflozin—Loss of consciousness—Doxorubicin—thyroid cancer	0.000247	0.00137	CcSEcCtD
Canagliflozin—SLC5A2—Disease—TPR—thyroid cancer	0.000247	0.0034	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—TPR—thyroid cancer	0.000247	0.0034	CbGpPWpGaD
Canagliflozin—Infection—Epirubicin—thyroid cancer	0.000246	0.00136	CcSEcCtD
Canagliflozin—Shock—Epirubicin—thyroid cancer	0.000244	0.00135	CcSEcCtD
Canagliflozin—Convulsion—Doxorubicin—thyroid cancer	0.000243	0.00135	CcSEcCtD
Canagliflozin—Nervous system disorder—Epirubicin—thyroid cancer	0.000243	0.00135	CcSEcCtD
Canagliflozin—SLC5A2—Disease—PRKAR1A—thyroid cancer	0.000243	0.00334	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PRKAR1A—thyroid cancer	0.000243	0.00334	CbGpPWpGaD
Canagliflozin—ABCC2—NRF2 pathway—RXRA—thyroid cancer	0.000242	0.00333	CbGpPWpGaD
Canagliflozin—Skin disorder—Epirubicin—thyroid cancer	0.000241	0.00133	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000238	0.00132	CcSEcCtD
Canagliflozin—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000236	0.00324	CbGpPWpGaD
Canagliflozin—Dry mouth—Doxorubicin—thyroid cancer	0.000234	0.0013	CcSEcCtD
Canagliflozin—SLC5A2—Disease—MEN1—thyroid cancer	0.000232	0.00319	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MEN1—thyroid cancer	0.000232	0.00319	CbGpPWpGaD
Canagliflozin—Hypotension—Epirubicin—thyroid cancer	0.000232	0.00128	CcSEcCtD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000231	0.00318	CbGpPWpGaD
Canagliflozin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.00023	0.00317	CbGpPWpGaD
Canagliflozin—Infection—Doxorubicin—thyroid cancer	0.000228	0.00126	CcSEcCtD
Canagliflozin—Shock—Doxorubicin—thyroid cancer	0.000226	0.00125	CcSEcCtD
Canagliflozin—Nervous system disorder—Doxorubicin—thyroid cancer	0.000225	0.00125	CcSEcCtD
Canagliflozin—Skin disorder—Doxorubicin—thyroid cancer	0.000223	0.00123	CcSEcCtD
Canagliflozin—UGT1A9—Biological oxidations—RXRA—thyroid cancer	0.000217	0.00299	CbGpPWpGaD
Canagliflozin—Hypotension—Doxorubicin—thyroid cancer	0.000214	0.00119	CcSEcCtD
Canagliflozin—UGT1A9—NRF2 pathway—NRG1—thyroid cancer	0.000214	0.00295	CbGpPWpGaD
Canagliflozin—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000214	0.00119	CcSEcCtD
Canagliflozin—Fatigue—Epirubicin—thyroid cancer	0.000214	0.00118	CcSEcCtD
Canagliflozin—Constipation—Epirubicin—thyroid cancer	0.000212	0.00117	CcSEcCtD
Canagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	0.00021	0.00288	CbGpPWpGaD
Canagliflozin—ABCC2—NRF2 pathway—NRG1—thyroid cancer	0.000209	0.00288	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000208	0.00286	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—TPR—thyroid cancer	0.000207	0.00284	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—TPR—thyroid cancer	0.000207	0.00284	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PRKAR1A—thyroid cancer	0.000203	0.0028	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PRKAR1A—thyroid cancer	0.000203	0.0028	CbGpPWpGaD
Canagliflozin—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000203	0.00112	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000198	0.0011	CcSEcCtD
Canagliflozin—Fatigue—Doxorubicin—thyroid cancer	0.000198	0.0011	CcSEcCtD
Canagliflozin—Urticaria—Epirubicin—thyroid cancer	0.000197	0.00109	CcSEcCtD
Canagliflozin—UGT1A9—PPARA activates gene expression—PPARG—thyroid cancer	0.000196	0.0027	CbGpPWpGaD
Canagliflozin—Constipation—Doxorubicin—thyroid cancer	0.000196	0.00109	CcSEcCtD
Canagliflozin—Abdominal pain—Epirubicin—thyroid cancer	0.000196	0.00109	CcSEcCtD
Canagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	0.000192	0.00264	CbGpPWpGaD
Canagliflozin—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000187	0.00104	CcSEcCtD
Canagliflozin—SLC5A2—Disease—CALCA—thyroid cancer	0.000185	0.00254	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CALCA—thyroid cancer	0.000185	0.00254	CbGpPWpGaD
Canagliflozin—Hypersensitivity—Epirubicin—thyroid cancer	0.000183	0.00101	CcSEcCtD
Canagliflozin—Urticaria—Doxorubicin—thyroid cancer	0.000182	0.00101	CcSEcCtD
Canagliflozin—Abdominal pain—Doxorubicin—thyroid cancer	0.000181	0.001	CcSEcCtD
Canagliflozin—Asthenia—Epirubicin—thyroid cancer	0.000178	0.000986	CcSEcCtD
Canagliflozin—Pruritus—Epirubicin—thyroid cancer	0.000175	0.000972	CcSEcCtD
Canagliflozin—Hypersensitivity—Doxorubicin—thyroid cancer	0.000169	0.000937	CcSEcCtD
Canagliflozin—SLC5A2—Disease—CDK1—thyroid cancer	0.000167	0.0023	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CDK1—thyroid cancer	0.000167	0.0023	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.000167	0.00229	CbGpPWpGaD
Canagliflozin—Asthenia—Doxorubicin—thyroid cancer	0.000164	0.000912	CcSEcCtD
Canagliflozin—Dizziness—Epirubicin—thyroid cancer	0.000164	0.000909	CcSEcCtD
Canagliflozin—Pruritus—Doxorubicin—thyroid cancer	0.000162	0.000899	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—TPR—thyroid cancer	0.00016	0.0022	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—MINPP1—thyroid cancer	0.00016	0.0022	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.000159	0.00219	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PRKAR1A—thyroid cancer	0.000157	0.00216	CbGpPWpGaD
Canagliflozin—Rash—Epirubicin—thyroid cancer	0.000156	0.000866	CcSEcCtD
Canagliflozin—Dermatitis—Epirubicin—thyroid cancer	0.000156	0.000865	CcSEcCtD
Canagliflozin—SLC5A2—Metabolism—SLC5A5—thyroid cancer	0.000155	0.00213	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—SLC5A5—thyroid cancer	0.000155	0.00213	CbGpPWpGaD
Canagliflozin—Dizziness—Doxorubicin—thyroid cancer	0.000152	0.000841	CcSEcCtD
Canagliflozin—Nausea—Epirubicin—thyroid cancer	0.000147	0.000816	CcSEcCtD
Canagliflozin—Rash—Doxorubicin—thyroid cancer	0.000145	0.000802	CcSEcCtD
Canagliflozin—Dermatitis—Doxorubicin—thyroid cancer	0.000144	0.000801	CcSEcCtD
Canagliflozin—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000143	0.00196	CbGpPWpGaD
Canagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000142	0.00195	CbGpPWpGaD
Canagliflozin—Nausea—Doxorubicin—thyroid cancer	0.000136	0.000755	CcSEcCtD
Canagliflozin—UGT1A9—Metabolism—NDUFA13—thyroid cancer	0.000136	0.00187	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—NRG1—thyroid cancer	0.000134	0.00185	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—NRG1—thyroid cancer	0.000134	0.00185	CbGpPWpGaD
Canagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	0.000132	0.00182	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—RXRA—thyroid cancer	0.00013	0.00179	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—RXRA—thyroid cancer	0.00013	0.00179	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—CP—thyroid cancer	0.00013	0.00179	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.00013	0.00179	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CHST14—thyroid cancer	0.000128	0.00176	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000123	0.00169	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—CP—thyroid cancer	0.000123	0.00169	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000121	0.00167	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000121	0.00166	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—TERT—thyroid cancer	0.000121	0.00166	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—TERT—thyroid cancer	0.000121	0.00166	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—SLC5A5—thyroid cancer	0.000119	0.00164	CbGpPWpGaD
Canagliflozin—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000116	0.00159	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HIF1A—thyroid cancer	0.000115	0.00159	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—HIF1A—thyroid cancer	0.000115	0.00159	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—HPGD—thyroid cancer	0.000103	0.00142	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—RXRA—thyroid cancer	0.0001	0.00138	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	9.73e-05	0.00134	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—PTGS2—thyroid cancer	9.66e-05	0.00133	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—BRAF—thyroid cancer	9.55e-05	0.00131	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—BRAF—thyroid cancer	9.55e-05	0.00131	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	9.21e-05	0.00127	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	9.17e-05	0.00126	CbGpPWpGaD
Canagliflozin—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	8.45e-05	0.00116	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—MINPP1—thyroid cancer	8.36e-05	0.00115	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	8.34e-05	0.00115	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PPARG—thyroid cancer	8.21e-05	0.00113	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PPARG—thyroid cancer	8.21e-05	0.00113	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—RXRA—thyroid cancer	7.74e-05	0.00106	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PTGS2—thyroid cancer	7.71e-05	0.00106	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PTGS2—thyroid cancer	7.71e-05	0.00106	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PRKAR1A—thyroid cancer	7.51e-05	0.00103	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—MINPP1—thyroid cancer	7.32e-05	0.00101	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TP53—thyroid cancer	7.24e-05	0.000996	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NDUFA13—thyroid cancer	7.11e-05	0.000978	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PTEN—thyroid cancer	6.73e-05	0.000925	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PTEN—thyroid cancer	6.73e-05	0.000925	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CHST14—thyroid cancer	6.68e-05	0.000919	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—TPR—thyroid cancer	6.6e-05	0.000909	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—CP—thyroid cancer	6.6e-05	0.000909	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	6.5e-05	0.000894	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PTGS2—thyroid cancer	6.46e-05	0.000889	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PTGS2—thyroid cancer	6.46e-05	0.000889	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PPARG—thyroid cancer	6.34e-05	0.000872	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NDUFA13—thyroid cancer	6.23e-05	0.000857	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—RXRA—thyroid cancer	6.14e-05	0.000845	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—NRAS—thyroid cancer	6e-05	0.000826	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—NRAS—thyroid cancer	6e-05	0.000826	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—TPR—thyroid cancer	5.91e-05	0.000813	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CHST14—thyroid cancer	5.85e-05	0.000805	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PRKAR1A—thyroid cancer	5.81e-05	0.0008	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	5.79e-05	0.000796	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	5.79e-05	0.000796	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	5.69e-05	0.000783	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PTEN—thyroid cancer	5.63e-05	0.000775	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PTEN—thyroid cancer	5.63e-05	0.000775	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HPGD—thyroid cancer	5.39e-05	0.000741	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	5.35e-05	0.000737	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.27e-05	0.000725	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—KRAS—thyroid cancer	5.16e-05	0.000711	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—KRAS—thyroid cancer	5.16e-05	0.000711	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTGS2—thyroid cancer	4.99e-05	0.000686	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IFNA2—thyroid cancer	4.97e-05	0.000684	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	4.94e-05	0.00068	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HPGD—thyroid cancer	4.72e-05	0.000649	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	4.55e-05	0.000626	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—MINPP1—thyroid cancer	4.51e-05	0.000621	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—SLC5A5—thyroid cancer	4.42e-05	0.000608	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HRAS—thyroid cancer	4.39e-05	0.000604	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—HRAS—thyroid cancer	4.39e-05	0.000604	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.37e-05	0.000601	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTEN—thyroid cancer	4.35e-05	0.000598	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	4.33e-05	0.000596	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—RXRA—thyroid cancer	4.15e-05	0.000571	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.14e-05	0.00057	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	4.11e-05	0.000566	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	3.97e-05	0.000546	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—AKT1—thyroid cancer	3.88e-05	0.000533	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—AKT1—thyroid cancer	3.88e-05	0.000533	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NDUFA13—thyroid cancer	3.84e-05	0.000528	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—RXRA—thyroid cancer	3.72e-05	0.000511	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	3.64e-05	0.000501	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.61e-05	0.000497	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CHST14—thyroid cancer	3.61e-05	0.000496	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—AKT1—thyroid cancer	3.25e-05	0.000447	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—AKT1—thyroid cancer	3.25e-05	0.000447	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—TPR—thyroid cancer	3.09e-05	0.000426	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	3.05e-05	0.000419	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PRKAR1A—thyroid cancer	3.04e-05	0.000419	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HPGD—thyroid cancer	2.91e-05	0.0004	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.76e-05	0.000379	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—TPR—thyroid cancer	2.71e-05	0.000373	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	2.71e-05	0.000373	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PRKAR1A—thyroid cancer	2.67e-05	0.000367	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—AKT1—thyroid cancer	2.51e-05	0.000345	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PPARG—thyroid cancer	2.35e-05	0.000323	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	2.32e-05	0.00032	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC5A5—thyroid cancer	2.32e-05	0.000319	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	2.29e-05	0.000315	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.17e-05	0.000299	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC5A5—thyroid cancer	2.03e-05	0.000279	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—RXRA—thyroid cancer	1.95e-05	0.000268	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.89e-05	0.00026	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NRAS—thyroid cancer	1.85e-05	0.000255	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTGS2—thyroid cancer	1.85e-05	0.000254	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—RXRA—thyroid cancer	1.7e-05	0.000235	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—TPR—thyroid cancer	1.67e-05	0.00023	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.64e-05	0.000226	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTEN—thyroid cancer	1.61e-05	0.000221	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—KRAS—thyroid cancer	1.6e-05	0.00022	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TP53—thyroid cancer	1.42e-05	0.000195	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—HRAS—thyroid cancer	1.36e-05	0.000187	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.25e-05	0.000172	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPARG—thyroid cancer	1.23e-05	0.000169	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—AKT1—thyroid cancer	1.2e-05	0.000165	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPARG—thyroid cancer	1.08e-05	0.000148	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—RXRA—thyroid cancer	1.05e-05	0.000144	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTGS2—thyroid cancer	9.66e-06	0.000133	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—AKT1—thyroid cancer	9.28e-06	0.000128	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTGS2—thyroid cancer	8.47e-06	0.000116	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTEN—thyroid cancer	8.43e-06	0.000116	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTEN—thyroid cancer	7.38e-06	0.000102	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPARG—thyroid cancer	6.63e-06	9.12e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTGS2—thyroid cancer	5.22e-06	7.18e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AKT1—thyroid cancer	4.86e-06	6.68e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTEN—thyroid cancer	4.55e-06	6.26e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AKT1—thyroid cancer	4.26e-06	5.85e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AKT1—thyroid cancer	2.62e-06	3.61e-05	CbGpPWpGaD
